Sponsored by:
About the Authors Lawrence A. Yannuzzi, MD Lawrence A. Yannuzzi, MD is a graduate of Harvard College and Boston University Medical School, where he was honored as a distinguished alumnus. He is the professor of clinical ophthalmology at Columbia University Medical School; vice-chairman and director of the Retinal Research
About the Authors Jasmine H. Francis, MD, FACS Dr. Francis is a board-certified ophthalmologist with specialty training in ophthalmic oncology and is an Associate Attending at Memorial Sloan Kettering Cancer Center. She sees patients with intraocular cancers such as uveal melanoma, lymphoma and retinoblastoma. She also participates in an interdisciplinary
About the Authors Julia Canestraro, OD, FAAO Instructor, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer CenterDr. Canestraro is an Instructor at Memorial Sloan Kettering Cancer Center, Ophthalmic Oncology Service. She has experience in the diagnosis and non-surgical management of ocular disease, including ocular tumors. She also specializes in treating the ocular
References Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology. 2017 Dec;124(12):1788-1798. doi: 10.1016/j.ophtha.2017.05.038. Epub 2017
Take Home Points MEKAR might mimic CSR at first glance – it is important to identify which retinal layer the fluid is accumulating MEKAR does not significantly impact vision and can return to normal without intervention
2 weeks later, still off drug.Vision and retina back to normal!Patient continues on drug to date with no recurrence of symptoms or subretinal fluid
Patient returns 1 month later with complaints of blurred vision OU x 10 days, which has been improving(oncologist HELD MEK inhibitor therapy due to reports of blurred vision)
48 yo F with cutaneous melanoma here for baseline exam prior to starting cobimetinib (MEK inhibitor) and atezolizumab (immunotherapy). No vision complaints
MEKAR (MEK Inhibitor Associated Retinopathy) May see various types of fluid configuration:A: Dome-shapedB: CaterpillarC: WavyD: Splitting
MEKAR (MEK Inhibitor Associated Retinopathy) Not associated with PEDs or choroidal thickening! (as seen in CSR) Example of central serous chorioretinopathy:
